HDAC9 and cancer: With the prominence of histone deacetylase (HDAC) inhibitors such as Vorinostat (92), along with DNA methylation inhibitors (93), modification of epigenetics and gene expression of cancer cells is also becoming a more prevalent route for novel cancer-treating drugs (Figure 2I).